What is claimed is:

1. A compound of Formula I:



(I)

or a stereoisomer, enantiomer, mixture of enantiomers, mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof; wherein:

R^1 is C_{6-14} aryl, heteroaryl, or heterocyclyl;

R^2 and R^3 are each independently C_{1-6} alkyl or C_{3-10} cycloalkyl;

wherein each alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with one or more substituents Q, where each Q is independently selected from halo, C_{1-6} alkyl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more C_{1-6} alkyl;

with the proviso that the compound is not 3-((3-chlorophenyl)amino)-5-((4-hydroxy-3,5-dimethylbenzyl)amino)-1*H*-pyrazole-4-carboxamide.

2. The compound of claim 1, wherein R^1 is C_{6-14} aryl or heteroaryl, each of which is optionally substituted with one or more substituents Q.

3. The compound of claim 1, wherein R^1 is C_{6-14} aryl, optionally substituted with one or more substituents Q.

4. The compound of any of claim 1, wherein R^1 is phenyl, optionally substituted with one or more substituents Q.

5. The compound of claim 4, wherein Q is independently selected from fluoro, chloro, bromo, iodo, methyl, morpholinyl, dimethylmorpholinyl, pyrrolyl, isopropylpiperazinyl, methylpiperazinyl, pyridinyl, and benzylpiperazinyl.

6. The compound of claim 3, wherein R^1 is 3-methyl-4-morpholinophenyl, 3-

chloro-4-morpholinophenyl, 4-morpholinophenyl, 4-(2,6-dimethylmorpholino)phenyl, 4-(1*H*-pyrrol-1-yl)phenyl, 4-(4-isopropylpiperazin-1-yl)phenyl, 4-(pyridin-2-yl)phenyl, 4-(4-methylpiperazin-1-yl)phenyl, 3-chloro-4-(2,6-dimethylmorpholino)phenyl, 4-(pyridin-3-yl)phenyl, or 3-chloro-4-(4-isopropylpiperazin-1-yl)phenyl.

7. The compound of claim 1, wherein R^1 is heteroaryl, optionally substituted with one or more substituents Q.

8. The compound of claim 7, wherein R^1 is 5- or 6-membered heteroaryl, each of which is optionally substituted with one or more substituents Q.

9. The compound of claim 8, wherein R^1 is pyridinyl, optionally substituted with one or more substituents Q.

10. The compound of claim 9, wherein R^1 is 2-morpholino-3-chloropyridin-5-yl, 2-morpholinopyridin-5-yl, 5-morpholinopyridin-2-yl, 2-morpholino-3-methylpyridin-5-yl, 2-(4-isopropylpiperazin-1-yl)-3-methylpyridin-5-yl, or 2-(4-methylpiperazin-1-yl)-3-methylpyridin-5-yl.

11. The compound of claim 1, wherein R^2 is C_{1-6} alkyl.

12. The compound of claim 1, wherein R^2 is methyl.

13. The compound of claim 1, wherein R^3 is C_{1-6} alkyl.

14. The compound of claim 1, wherein R^3 is methyl.

15. The compound of claim 1 selected from the group consisting of:



1



2



3



4



5



6



7



8



9



10



11



12



13



14



15



16



,

17

and stereoisomers, enantiomers, mixtures of enantiomers, and mixtures of diastereomers thereof; and pharmaceutically acceptable salts thereof.

16. A pharmaceutical composition comprising the compound of claim 1, and one or more pharmaceutically acceptable excipients.

17. The pharmaceutical composition of claim 16, wherein the composition is formulated for single dose administration.

18. The pharmaceutical composition of claim 16, wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

19. The pharmaceutical composition of claim 18, wherein the oral dosage form is a tablet or capsule.

20. The pharmaceutical composition of claim 16, further comprising a second therapeutic agent.

21. A compound of Formula I:



(I)

or a stereoisomer, enantiomer, mixture of enantiomers, or mixture of diastereomers thereof; or a pharmaceutically acceptable salt thereof; wherein:

R^1 is C_{6-14} aryl, heteroaryl, or heterocyclyl;

R^2 and R^3 are each independently C_{1-6} alkyl or C_{3-10} cycloalkyl;

wherein each alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl is optionally substituted with one or more substituents Q, where each Q is independently selected from halo, C_{1-6} alkyl, C_{1-6} alkoxy, aryl, heteroaryl, and heterocyclyl, each of which is further optionally substituted with one or more C_{1-6} alkyl, halo, aralkyl, dialkylamino, heterocyclyl, heterocyclylalkyl, and heterocyclylcarbonyl;

with the proviso that the compound is not 3-((3-chlorophenyl)amino)-5-((4-hydroxy-3,5-dimethylbenzyl)amino)-1*H*-pyrazole-4-carboxamide.

22. The compound of claim 21, wherein R^1 is C_{6-14} aryl or heteroaryl, each of which is optionally substituted with one or more substituents Q.

23. The compound of claim 21, wherein R^1 is C_{6-14} aryl, optionally substituted with one or more substituents Q.

24. The compound of claim 21, wherein R^1 is phenyl, optionally substituted with one or more substituents Q.

25. The compound of claim 24, wherein Q is independently selected from fluoro, chloro, bromo, iodo, methyl, morpholinyl, dimethylmorpholinyl, pyrrolyl, isopropylpiperazinyl, methylpiperazinyl, pyridinyl, benzylpiperazinyl, phenyl, imidazolyl, methoxy, *tert*-butyl, indazolyl, methylpipiperidinyl, (pyrrolidinecarbonyl)piperazinyl, flouropiperidinyl, dimethylpyranyl, piperidinyl, benzyl, 1,1-dioxidothiomorpholino, pyrrolidinylmethyl, dimethylamino, oxazolyl, (piperidinecarbonyl)piperazinyl, acetamido, (pyrimidinyl)piperizinyl, piperidinylmethyl, thiomorpholinyl fluorophenylamido, methoxyphenylamido, isopropylpiperidinyl, cyanomethyl, (trifluoromethyl)phenylamido, and oxomorpholinyl.

26. The compound of claim 23, wherein R^1 is 3-methyl-4-morpholinophenyl, 3-chloro-4-morpholinophenyl, 4-morpholinophenyl, 4-(2,6-dimethylmorpholino)phenyl, 4-(1*H*-pyrrol-1-yl)phenyl, 4-(4-isopropylpiperazin-1-yl)phenyl, 4-(pyridin-2-yl)phenyl, 4-(4-

methylpiperazin-1-yl)phenyl, 3-chloro-4-(2,6-dimethylmorpholino)phenyl, 4-(pyridin-3-yl)phenyl, 3-chloro-4-(4-isopropylpiperazin-1-yl)phenyl, 1,1'-biphenyl, 4-(1*H*-imidazol-1-yl)phenyl, 4-methoxyphenyl, 4-*tert*-butylphenyl, 4-(4-methyl-[1,4'-bipiperidin]-1'-yl)phenyl, 4-(4-(morpholine-4-carbonyl)piperazin-1-yl)phenyl, 4-(4-fluoropiperidin-1-yl)phenyl, 4-(piperidin-1-yl)phenyl. 3-chloro-4-(2,6-dimethylmorpholino)phenyl, 3-methyl-4-(4-methylpiperazin-1-yl)phenyl, 3-methyl-4-(piperidin-1-yl)phenyl, 4-(4-benzylpiperazin-1-yl)-3-methylphenyl, 4-(1,1-dioxidothiomorpholino)phenyl, (5-(piperidin-1-yl)pyridine-2-yl)phenyl, 4-(4-chloropiperidin-1-yl)phenyl, 4-(pyrrolidin-1-ylmethyl)phenyl, 4-(4-(dimethylamino)piperidin-1-yl)phenyl, 3-fluoro-4-morpholinophenyl, 4-(oxazol-5-yl)phenyl, 4-(4-(piperidine-1-carbonyl)piperazin-1-yl)phenyl, 3-acetamidophenyl, 3-chloro-4-(4-methylpiperazin-1-yl)phenyl, 4-fluorophenyl, 3-cyanophenyl, 4-(4-(pyrimidin-2-yl)piperazin-1-yl)phenyl, 4-(piperidin-1-ylmethyl)phenyl, 4-thiomorpholinophenyl, 4-aminophenyl, 4-(aminosulfonyl)phenyl, 4-(dimethylamino)phenyl, 4-(morpholinomethyl)phenyl. 2-methoxyphenyl, 4-(4-fluorophenylamido)phenyl, 4-(4,5-dihydro-1*H*-pyrazol-3-yl)phenyl, 4-(2-methoxyphenylamido)phenyl, 4-(3-methoxyphenylamido)phenyl, 4-(4-methoxyphenylamido)phenyl, 4-(4-isopropylpiperidin-1-yl)phenyl 4-(3-oxomorpholinyl)phenyl, 4-(2-cyanomethyl)phenyl, 4((4-trifluoromethyl)phenylamido)phenyl, or 4-(4-methylpiperidin-1-yl)phenyl.

27. The compound of claim 21, wherein R^1 is heteroaryl, optionally substituted with one or more substituents Q.

28. The compound of claim 27, wherein R^1 is 5- or 6-membered heteroaryl, each of which is optionally substituted with one or more substituents Q.

29. The compound of claim 27, wherein R^1 is indazolyl, optionally substituted with one or more substituents Q.

30. The compound of claim 28, wherein R^1 is pyridinyl, optionally substituted with one or more substituents Q.

31. The compound of claim 30, wherein R^1 is 2-morpholino-3-chloropyridin-5-yl, 2-morpholinopyridin-5-yl, 5-morpholinopyridin-2-yl, 2-morpholino-3-methylpyridin-5-yl, 2-(4-isopropylpiperazin-1-yl)-3-methylpyridin-5-yl, 2-(4-methylpiperazin-1-yl)-3-methylpyridin-5-yl,

6-(2,6-dimethyltetrahydro-2*H*-pyran-4-yl)pyridin-3-yl, or 2-(4-(pyrrolidin-1-yl)piperidin-1-yl)pyridin-5-yl.

32. The compound of claim 21, wherein R^2 is C_{1-6} alkyl.

33. The compound of claim 21, wherein R^2 is methyl.

34. The compound of claim 21, wherein R^3 is C_{1-6} alkyl.

35. The compound of claim 21, wherein R^3 is methyl.

36. The compound of claim 21 selected from the group consisting of:



1



2



3



4



5



6



7



8



9



10



11



12



13



14



15



16



17



18



19



20



21



22



23



24



25



26



27



28



29



,

30



,

31



,

32



,

33



,

34



,

35



,

36



,

37



38



39



40



41



42



43



44



45



,

46



,

47



,

48



,

49



,

50



,

51



,

52



,

53



,



,

54



,

55



,

56



,

57



,

58

,

59



,

61



,

62



,

63

and stereoisomers, enantiomers, mixtures of enantiomers, and mixtures of diastereomers thereof; and pharmaceutically acceptable salts thereof.

37. A pharmaceutical composition comprising the compound of claim 21, and one or

more pharmaceutically acceptable excipients.

38. The pharmaceutical composition of claim 37, wherein the composition is formulated for single dose administration.

39. The pharmaceutical composition of claim 37, wherein the composition is formulated as oral, parenteral, or intravenous dosage form.

40. The pharmaceutical composition of claim 39, wherein the oral dosage form is a tablet or capsule.

41. The pharmaceutical composition of claim 37, further comprising a second therapeutic agent.